Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

ENDRA Life Sciences (NDRA) Shares Issued (2017 - 2025)

ENDRA Life Sciences has reported Shares Issued over the past 5 years, most recently at -$7.5 million for Q4 2021.

Quarterly Shares Issued fell 6749.67% to -$7.5 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2021, down 41.44% year-over-year, with the annual reading at $1.2 million for FY2025, 7.75% down from the prior year.
Shares Issued was -$7.5 million for Q4 2021 at ENDRA Life Sciences, down from $7.5 million in the prior quarter.
Over five years, Shares Issued peaked at $9.8 million in Q1 2021 and troughed at -$7.5 million in Q4 2021.
The 4-year median for Shares Issued is $2.4 million (2020), against an average of $2.4 million.
The largest YoY upside for Shares Issued was 24871.44% in 2021 against a maximum downside of 62713.09% in 2021.
A 4-year view of Shares Issued shows it stood at $8.6 million in 2017, then decreased by 9.94% to $7.7 million in 2018, then crashed by 98.54% to $112927.0 in 2020, then crashed by 6749.67% to -$7.5 million in 2021.
Per Business Quant, the three most recent readings for NDRA's Shares Issued are -$7.5 million (Q4 2021), $7.5 million (Q3 2021), and -$7.0 million (Q2 2021).